Vedere Bio's targets include inherited retinal dystrophies.
The agreements relate to violations in Greece, Vietnam and South Korea.
It will continue developing the company's technology.
9 of the latest products available and how to educate patients about them.
The goal was to help diabetes patients.
The eyecare business will be a standalone company. Novartis announced that it will spin off Alcon, its eyecare division, into a separately traded standalone company. The...
The firm is working on a treatment for diabetic macular edema. LAUSANNE, SWITZERLAND — Oculis, a biotechnology company focused on eye drops, has closed a $20.3...
The site beat out 2 non-US locations. Alcon will invest $97 million to expand production capacity at a plant near Atlanta. The project at the Johns Creek...
He’ll start on June 1. (Press Release) FORT WORTH, TX – Alcon, a division of Novartis, has appointed Dr. Stephen S. Lane as chief medical officer and...
The deal closed Jan. 20. Novartis paid $465 million for Encore Vision Inc., a privately held company in Fort Worth, TX, reports DallasNews.com. The acqusition was...
Alcon’s sales fell 3 percent in 2016. The CEO of Novartis said the company continues to mull the possibility of spinning off its Alcon eyecare unit....
It’s a “potentially disruptive innovation,” Novartis says. Novartis plans to acquire Encore Vision Inc., a privately held company in Fort Worth, TX, focused on the development...
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
